CEACAM5 and cancer: This study suggests that NEO-201 could be a good anti-glycan mAb for the treatment of different types of cancers not only expressing core 1 and/or extended core 1 O-glycans attached to the tumor-associated variant of CEACAM5 and CEACAM6 but also to other tumor-associated proteins.